Rocket Pharmaceuticals Stock Surges 34% on FDA Alignment for Danon Disease Treatment
12 Settembre 2023 - 11:28PM
Dow Jones News
By Sabela Ojea
Shares of Rocket Pharmaceuticals surged 34% to $20.46 in
post-market trading on Tuesday after the company said it reached
alignment with the Food and Drug Administration regarding its Phase
2 trial for the treatment of Danon disease.
The Cranbury, N.J.-based pharmaceutical company said its study
would evaluate the use of the investigational gene therapy RP-A501
to treat 12 patients with Danon disease.
Danon is a rare genetic disorder that has no cure, and is known
for weakening the heart and movement muscles, as well as
intellectual disability.
The trial will support accelerated approval of Rocket's
treatment by the FDA.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 12, 2023 17:13 ET (21:13 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Rocket Pharmaceuticals (NASDAQ:RCKT)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Rocket Pharmaceuticals (NASDAQ:RCKT)
Storico
Da Mag 2023 a Mag 2024
